HK1117524A1 - Process for the syntesis of 5-(methyl-1h-imidazol-1-yl)-3-(tri fluorome th yl)-benzeneamine - Google Patents

Process for the syntesis of 5-(methyl-1h-imidazol-1-yl)-3-(tri fluorome th yl)-benzeneamine

Info

Publication number
HK1117524A1
HK1117524A1 HK08108277.9A HK08108277A HK1117524A1 HK 1117524 A1 HK1117524 A1 HK 1117524A1 HK 08108277 A HK08108277 A HK 08108277A HK 1117524 A1 HK1117524 A1 HK 1117524A1
Authority
HK
Hong Kong
Prior art keywords
syntesis
benzeneamine
imidazol
methyl
tri fluorome
Prior art date
Application number
HK08108277.9A
Other languages
English (en)
Inventor
Joseph Mckenna
Wen-Chung Shieh
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HK1117524A1 publication Critical patent/HK1117524A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
HK08108277.9A 2005-06-09 2008-07-25 Process for the syntesis of 5-(methyl-1h-imidazol-1-yl)-3-(tri fluorome th yl)-benzeneamine HK1117524A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68897705P 2005-06-09 2005-06-09
US70559005P 2005-08-04 2005-08-04
PCT/US2006/022155 WO2006135641A2 (fr) 2005-06-09 2006-06-07 Procede de synthese de composes organiques

Publications (1)

Publication Number Publication Date
HK1117524A1 true HK1117524A1 (en) 2009-01-16

Family

ID=37091153

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08108277.9A HK1117524A1 (en) 2005-06-09 2008-07-25 Process for the syntesis of 5-(methyl-1h-imidazol-1-yl)-3-(tri fluorome th yl)-benzeneamine

Country Status (32)

Country Link
US (2) US8124763B2 (fr)
EP (1) EP1924574B1 (fr)
JP (1) JP5118024B2 (fr)
KR (3) KR101514593B1 (fr)
AR (1) AR053890A1 (fr)
AT (1) ATE487709T1 (fr)
AU (1) AU2006258051B2 (fr)
BR (1) BRPI0611663A2 (fr)
CA (1) CA2610105C (fr)
CY (1) CY1111428T1 (fr)
DE (1) DE602006018156D1 (fr)
DK (1) DK1924574T3 (fr)
EC (1) ECSP077982A (fr)
EG (1) EG25039A (fr)
GT (1) GT200600217A (fr)
HK (1) HK1117524A1 (fr)
IL (1) IL187421A (fr)
JO (1) JO2636B1 (fr)
MA (1) MA29599B1 (fr)
MX (1) MX2007015423A (fr)
MY (1) MY147436A (fr)
NO (1) NO340743B1 (fr)
NZ (1) NZ563740A (fr)
PE (1) PE20070015A1 (fr)
PL (1) PL1924574T3 (fr)
PT (1) PT1924574E (fr)
RU (1) RU2444520C2 (fr)
SA (1) SA06270147B1 (fr)
SI (1) SI1924574T1 (fr)
TN (1) TNSN07463A1 (fr)
TW (1) TWI430999B (fr)
WO (1) WO2006135641A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200600316A (es) * 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
US8242271B2 (en) 2007-06-04 2012-08-14 Avila Therapeutics, Inc. Heterocyclic compounds and uses thereof
EP2305667A3 (fr) 2008-07-17 2011-05-11 Teva Pharmaceutical Industries Ltd. Produits intermédiaires du nilotinib et préparation de ceux-ci
EP2530081A3 (fr) 2008-11-05 2013-04-10 Teva Pharmaceutical Industries, Ltd. Formes cristallines du nilotinib HCI
WO2010060074A1 (fr) * 2008-11-24 2010-05-27 Teva Pharmaceutical Industries Ltd. Synthèse du nilotinib et ses intermédiaires
US20110053968A1 (en) * 2009-06-09 2011-03-03 Auspex Pharmaceuticals, Inc. Aminopyrimidine inhibitors of tyrosine kinase
JO3634B1 (ar) 2009-11-17 2020-08-27 Novartis Ag طريقة لعلاج اضطرابات تكاثرية وحالات مرضية أخرى متوسطة بنشاط كيناز bcr-abl، c-kit، ddr1، ddr2، أو pdgf-r
JP5841234B2 (ja) 2011-03-31 2016-01-13 ザ プロクター アンド ギャンブルカンパニー フケ／脂漏性皮膚炎の治療に有効な皮膚活性剤を特定及び評価するためのシステム、モデル、及び方法
AR086913A1 (es) * 2011-06-14 2014-01-29 Novartis Ag 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas
WO2013120852A1 (fr) 2012-02-13 2013-08-22 Grindeks, A Joint Stock Company Intermédiaires pour un nouveau procédé de préparation d'imatinib et d'inhibiteurs de tyrosine kinase associés
US9920357B2 (en) 2012-06-06 2018-03-20 The Procter & Gamble Company Systems and methods for identifying cosmetic agents for hair/scalp care compositions
WO2015092624A1 (fr) 2013-12-16 2015-06-25 Ranbaxy Laboratories Limited Mono-oxalate de nilotinib et sa forme cristalline
CN103694176B (zh) 2014-01-07 2015-02-18 苏州立新制药有限公司 尼洛替尼中间体的制备方法
EP3095782A1 (fr) 2015-05-18 2016-11-23 Esteve Química, S.A. Nouveau procédé de préparation de 3- (4-methyl-1h-imidazol-1-yl) -5- (trifluorométhyl) benzénamine
US11666888B2 (en) 2018-02-05 2023-06-06 Bio-Rad Laboratories, Inc. Chromatography resin having an anionic exchange-hydrophobic mixed mode ligand
JP7409696B2 (ja) 2018-06-15 2024-01-09 ハンダ ファーマシューティカルズ インコーポレイテッド キナーゼ阻害剤の塩およびその組成物
JP2020007240A (ja) * 2018-07-04 2020-01-16 住友化学株式会社 ベンズアミド化合物の製造方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5136082A (en) * 1990-08-03 1992-08-04 Himont Incorporated Process for preparing organic esters and amides and catalyst system therefor
CA2151491A1 (fr) 1992-12-24 1994-07-07 Robert J. Kaufman Emulsions a base de fluorocarbures
TW406020B (en) 1993-09-29 2000-09-21 Bristol Myers Squibb Co Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent
US5597829A (en) 1994-05-09 1997-01-28 Bionumerik Pharmaceuticals, Inc. Lactone stable formulation of camptothecin and methods for uses thereof
US5726181A (en) 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
US6323366B1 (en) 1997-07-29 2001-11-27 Massachusetts Institute Of Technology Arylamine synthesis
AR013261A1 (es) 1997-08-01 2000-12-13 Smithkline Beecham Corp Formulaciones farmaceuticas para analogos de camptotecina en capsula de gelatina
US20030059465A1 (en) 1998-05-11 2003-03-27 Unger Evan C. Stabilized nanoparticle formulations of camptotheca derivatives
US6395916B1 (en) 1998-07-10 2002-05-28 Massachusetts Institute Of Technology Ligands for metals and improved metal-catalyzed processes based thereon
DE69901379T2 (de) 1999-03-09 2002-11-07 Sigma Tau Ind Farmaceuti Camptothecin-Derivate mit Antitumor-Wirkung
IT1306129B1 (it) 1999-04-13 2001-05-30 Sigma Tau Ind Farmaceuti Esteri della l-carnitina o di alcanoil l-carnitine utilizzabili comelipidi cationici per l'immissione intracellulare di composti
DE19926056B4 (de) 1999-06-08 2004-03-25 Gkss-Forschungszentrum Geesthacht Gmbh Einrichtung zur Analyse atomarer und/oder molekularer Elemente mittels wellenlängendispersiver, röntgenspektrometrischer Einrichtungen
GB9918885D0 (en) 1999-08-10 1999-10-13 Pharmacia & Upjohn Spa Pharmaceutical formulations in hydroxypropymethycellulose capsules
GB9925127D0 (en) 1999-10-22 1999-12-22 Pharmacia & Upjohn Spa Oral formulations for anti-tumor compounds
US20040009229A1 (en) 2000-01-05 2004-01-15 Unger Evan Charles Stabilized nanoparticle formulations of camptotheca derivatives
US20020150615A1 (en) 2001-02-12 2002-10-17 Howard Sands Injectable pharmaceutical composition comprising microdroplets of a camptothecin
US6653319B1 (en) 2001-08-10 2003-11-25 University Of Kentucky Research Foundation Pharmaceutical formulation for poorly water soluble camptothecin analogues
US6629598B2 (en) 2001-08-10 2003-10-07 Vinod K. Narula Flexible ribbed splint system
CA2461556A1 (fr) 2001-10-15 2003-04-24 Crititech, Inc. Compositions et procedes destines a l'administration de microparticules de medicaments faiblement hydrosolubles et procedes de traitement associes
US20060078618A1 (en) 2001-12-11 2006-04-13 Constantinides Panayiotis P Lipid particles and suspensions and uses thereof
JP2003267891A (ja) 2002-03-13 2003-09-25 Mitsubishi-Kagaku Foods Corp Ｗ／ｏ／ｗ型エマルション製剤
FR2840303B1 (fr) 2002-05-31 2005-07-15 Rhodia Chimie Sa Procede d'arylation ou de vinylation ou d'alcylynation d'un compose nucleophile
CZ294371B6 (cs) 2002-06-10 2004-12-15 Pliva - Lachema, A. S. Stabilizovaná farmaceutická kompozice na bázi polyoxyethylovaného ricinového oleje a způsob její přípravy
EP1393719A1 (fr) 2002-08-23 2004-03-03 Munich Biotech AG Compositions à base de carboxylate de camptothécine
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
JP4426749B2 (ja) 2002-07-11 2010-03-03 株式会社産学連携機構九州 Ｏ／ｗ型エマルション製剤
US20040171560A1 (en) 2002-12-23 2004-09-02 Dabur Research Foundation Stabilized pharmaceutical composition
JP2006199590A (ja) 2003-09-04 2006-08-03 Nano Career Kk 水溶性の塩基性薬物内包ナノ粒子含有組成物
WO2005042539A1 (fr) 2003-10-29 2005-05-12 Sonus Pharmaceuticals, Inc. Composes medicamenteux a base de tocopherol modifie
WO2005060871A1 (fr) 2003-12-17 2005-07-07 Bionumerik Pharmaceuticals, Inc. Preparations pharmaceutiques de camptothecines et leur procede d'obtention
GT200500310A (es) 2004-11-19 2006-06-19 Compuestos organicos

Also Published As

Publication number Publication date
JP5118024B2 (ja) 2013-01-16
MX2007015423A (es) 2008-02-21
ECSP077982A (es) 2008-01-23
DE602006018156D1 (de) 2010-12-23
JP2008545786A (ja) 2008-12-18
TNSN07463A1 (en) 2009-03-17
PT1924574E (pt) 2011-02-08
DK1924574T3 (da) 2011-02-14
KR101514593B1 (ko) 2015-04-22
KR20080022093A (ko) 2008-03-10
CY1111428T1 (el) 2015-08-05
WO2006135641A3 (fr) 2007-03-29
GT200600217A (es) 2007-03-28
EP1924574A2 (fr) 2008-05-28
MY147436A (en) 2012-12-14
EP1924574B1 (fr) 2010-11-10
NO340743B1 (no) 2017-06-12
BRPI0611663A2 (pt) 2010-09-28
PE20070015A1 (es) 2007-02-06
NZ563740A (en) 2011-03-31
MA29599B1 (fr) 2008-07-01
AU2006258051B2 (en) 2010-09-09
EG25039A (en) 2011-07-06
AR053890A1 (es) 2007-05-23
PL1924574T3 (pl) 2011-04-29
IL187421A0 (en) 2008-02-09
CA2610105A1 (fr) 2006-12-21
WO2006135641A2 (fr) 2006-12-21
SI1924574T1 (sl) 2011-02-28
US20120116081A1 (en) 2012-05-10
KR20130118394A (ko) 2013-10-29
CA2610105C (fr) 2014-03-25
US8124763B2 (en) 2012-02-28
KR20120066067A (ko) 2012-06-21
AU2006258051A1 (en) 2006-12-21
SA06270147B1 (ar) 2009-12-22
RU2007148231A (ru) 2009-07-20
TWI430999B (zh) 2014-03-21
NO20080157L (no) 2008-01-09
US8946416B2 (en) 2015-02-03
JO2636B1 (en) 2012-06-17
ATE487709T1 (de) 2010-11-15
TW200726756A (en) 2007-07-16
IL187421A (en) 2011-11-30
RU2444520C2 (ru) 2012-03-10
KR101216249B1 (ko) 2012-12-28
US20080188656A1 (en) 2008-08-07

Similar Documents

Publication Publication Date Title
HK1117524A1 (en) Process for the syntesis of 5-(methyl-1h-imidazol-1-yl)-3-(tri fluorome th yl)-benzeneamine
SI1948615T1 (sl) Derivati pirazola, uporabni za zdravljenje ginekoloških obolenj
ZA200704468B (en) Process for the stabilization of dusting surfaces
PL1743882T3 (pl) Sposób do produkcji izocyjanianów
HK1102030A1 (en) Process for the synthesis of azetidinones
IL185419A0 (en) Improved process for the synthesis of enantiomeric indanylamine derivatives
PL1896425T3 (pl) Sposób wytwarzania 5-(metylo-1H-1-ilo)-3-trifluorometylo)-benzenoaminy
EP1922345A4 (fr) Procede destine a la preparation d'un copolymere-1
PL1807395T3 (pl) Sposób syntezy n-alkoksyamin
IL177315A0 (en) Process for the preparation of substituted triazole compounds
EP1951709A4 (fr) Composes d imidazolidinone utiles en tant qu inhibiteurs de la beta-secretase lors du traitement de la maladie d alzheimer
IL183379A0 (en) Processes for the preparation of linezolid intermediate
PL1968996T3 (pl) Sposób wytwarzania żelazo-sukcynylokazeiny
ZA200710389B (en) Process for the copolymerization of propylene
ZA200601910B (en) Process for the preparation of organosilances
IL182421A0 (en) Process for the preparation of pyrazoles
PL1937662T3 (pl) Sposób wytwarzania duloksetyny
GB0402262D0 (en) Process for the manufacture of organic compounds
ZA200800921B (en) Pyrazolone derivatives for the treatment of tuberculosis
SG121993A1 (en) Process for influencing the properties of combustion residue
HK1128287A1 (en) Process for the preparation of tryptase inhibitors
IL185076A0 (en) Process for the prepartion of enantiomerically pure 1-substituted-3-aminoalcohols
ZA200607540B (en) Process for the preparation of substituted triazole compounds
PL1940926T3 (pl) Sposób powlekania przedmiotów
IL178237A0 (en) Process for the preparation of rosiglitazone